Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024


REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.

Continue reading here:
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Related Posts